Adaptive Immunity in Ankylosing Spondylitis: Phenotype and Functional Alterations of T-Cells before and during Infliximab Therapy
Figure 3
Nitric oxide generation kinetics in CD4+ and CD8+ cells following activation in healthy controls and ankylosing spondylitis patients before infliximab (IFX) therapy then 2 and 6 weeks after initiation of IFX ( and 8, resp.). AUC: area under the curve. For details of IFX therapy, see text.
